From NAFLD in clinical practice to answers from guidelines
Fabio Nascimbeni,Raluca Pais,Stefano Bellentani,Christopher P. Day,V. Ratziu,Paola Loria,Amedeo Lonardo +6 more
Reads0
Chats0
TLDR
This review of the literature consists of three sections: papers concerning non-alcoholic fatty liver disease awareness among the general population, general practitioners, and liver and non-liver specialists, and clinical practice guidelines issued by International and National Hepatological Scientific Societies.About:
This article is published in Journal of Hepatology.The article was published on 2013-10-01 and is currently open access. It has received 327 citations till now. The article focuses on the topics: Population.read more
Citations
More filters
Journal ArticleDOI
Nonalcoholic Fatty Liver Disease: A Systematic Review
TL;DR: How to identify patients with nonalcoholic fatty liver disease at greatest risk of non Alcoholic steatohepatitis and cirrhosis is illustrated and the role and limitations of current diagnostics and liver biopsy are discussed to provide an outline for the management of patients across the spectrum of non alcoholic fatty Liver disease.
Journal ArticleDOI
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez,Yadina Martinez-Perez,Luis Calzadilla-Bertot,Ana Torres-Gonzalez,Bienvenido Gra-Oramas,Licet Gonzalez-Fabian,Scott L. Friedman,Moisés Diago,Manuel Romero-Gómez +8 more
TL;DR: A greater extent of weight loss, induced by lifestyle changes, is associated with the level of improvement in histologic features of NASH.
Journal ArticleDOI
Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.
TL;DR: In this paper, the authors identified and summarized longitudinal studies that, supporting the association of nonalcoholic fatty liver disease with either type 2 diabetes mellitus or metabolic syndrome, suggest that non-ALTL disease precedes the development of both conditions.
Journal ArticleDOI
Non-alcoholic fatty liver disease: An expanded review
Mark Benedict,Xuchen Zhang +1 more
TL;DR: The current knowledge of non-alcoholic fatty liver disease epidemiology, risk factors, diagnosis, pathogenesis, pathologic changes, natural history, and treatment is summarized to aid in further understanding this disease and better managing NAFLD patients.
Journal ArticleDOI
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.
Stefano Ballestri,Stefano Zona,Giovanni Targher,Dante Romagnoli,Enrica Baldelli,Fabio Nascimbeni,Alberto Roverato,Giovanni Guaraldi,Amedeo Lonardo +8 more
TL;DR: Patients with nonalcoholic fatty liver disease diagnosed by either serum liver enzymes (aminotransferases or gamma‐glutamyltransferase [GGT]) or ultrasonography are gauged for the risk of developing type 2 diabetes and metabolic syndrome.
References
More filters
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National
William C. Taylor,Nigel Unwin +1 more
Journal Article
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Scott M. Grundy,Diane M. Becker,Luther T. Clark,Richard S. Cooper,Margo A. Denke,James P. Howard,Donald B. Hunninghake,D. Roger Illingworth,Russell V. Luepker,Patrick E. McBride,James M. McKenney,Richard C. Pasternak,Neil J. Stone,Linda Van Horn +13 more
Journal ArticleDOI
Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Scott M. Grundy,James I. Cleeman,Stephen R. Daniels,Karen A. Donato,Robert H. Eckel,Barry A. Franklin,David Gordon,Ronald M. Krauss,Peter J. Savage,Sidney C. Smith,John A. Spertus,Fernando Costa +11 more
TL;DR: This statement from the American Heart Association and the National Heart, Lung, and Blood Institute is intended to provide up-to-date guidance for professionals on the diagnosis and management of the metabolic syndrome in adults.
Journal ArticleDOI
The metabolic syndrome—a new worldwide definition
Journal ArticleDOI
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
TL;DR: Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.